Canadian Atrial Fibrillation Anticoagulation Study "CAFA"

Completed

Phase N/A Results

Results

The annual rates of the primary outcome event cluster were 3.5% in warfarin-treated and 5.2% in placebo-treated patients, with a relative risk reduction of 37% (95% confidence limits, -63.5%, 75.5%, p = 0.17).